As of 2026-03-17, the Relative Valuation of Kymera Therapeutics Inc (KYMR) is (87.14) USD. This relative valuation is based on P/E multiples. With the latest stock price at 79.60 USD, the upside of Kymera Therapeutics Inc based on Relative Valuation is -209.5%.
The range of the Relative Valuation is (82.38) - (87.72) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.2x - 25.6x | 23.4x |
| Forward P/E multiples | 21.6x - 23.0x | 22.3x |
| Fair Price | (82.38) - (87.72) | (87.14) |
| Upside | -203.5% - -210.2% | -209.5% |
| Date | P/E |
| 2026-03-13 | -20.72 |
| 2026-03-12 | -20.32 |
| 2026-03-11 | -21.38 |
| 2026-03-10 | -22.18 |
| 2026-03-09 | -22.30 |
| 2026-03-06 | -21.89 |
| 2026-03-05 | -21.90 |
| 2026-03-04 | -22.58 |
| 2026-03-03 | -22.64 |
| 2026-03-02 | -23.63 |
| 2026-02-27 | -23.95 |
| 2026-02-26 | -24.92 |
| 2026-02-25 | -23.78 |
| 2026-02-24 | -23.86 |
| 2026-02-23 | -23.19 |
| 2026-02-20 | -22.92 |
| 2026-02-19 | -22.68 |
| 2026-02-18 | -22.32 |
| 2026-02-17 | -22.25 |
| 2026-02-13 | -21.59 |
| 2026-02-12 | -22.03 |
| 2026-02-11 | -21.57 |
| 2026-02-10 | -20.84 |
| 2026-02-09 | -20.72 |
| 2026-02-06 | -20.87 |
| 2026-02-05 | -19.91 |
| 2026-02-04 | -20.37 |
| 2026-02-03 | -20.25 |
| 2026-02-02 | -19.83 |
| 2026-01-30 | -19.06 |
| 2026-01-29 | -19.38 |
| 2026-01-28 | -18.66 |
| 2026-01-27 | -18.92 |
| 2026-01-26 | -18.63 |
| 2026-01-23 | -18.34 |
| 2026-01-22 | -19.08 |
| 2026-01-21 | -18.55 |
| 2026-01-20 | -17.87 |
| 2026-01-16 | -18.23 |
| 2026-01-15 | -18.65 |
| 2026-01-14 | -19.72 |
| 2026-01-13 | -19.44 |
| 2026-01-12 | -19.17 |
| 2026-01-09 | -19.61 |
| 2026-01-08 | -19.66 |
| 2026-01-07 | -20.11 |
| 2026-01-06 | -19.26 |
| 2026-01-05 | -18.99 |
| 2026-01-02 | -19.08 |
| 2025-12-31 | -20.40 |